LMS EXPANDS SALES AND MARKETING EFFORTS

Click here for the PDF version of this release
Click to return to Press Releases

Montreal, Quebec, May 29, 2008 – LMS Medical Systems (TSX:LMZ), a healthcare
technology company and developer of the CALM® patient safety software systems for
obstetrics, today announced that Donald H. Bauman, Jr. has joined LMS as Vice
President and General Manager of Sales and Marketing. With this addition, LMS is
responding to the ever growing demand for its obstetrical offerings.

Mr. Bauman brings over 20 years of field experience to LMS. In past assignments, he has
been successful in accelerating market penetration of innovative technologies that have
transformed healthcare practices and increased patient safety, including enterprise clinical
systems, medication management and infection prevention. He has also developed
networks of complementary resources and partners to enhance the value of offerings.

“Improving obstetrical outcomes through risk reduction is gaining heightened attention
with clinicians, hospitals and insurers,” said Diane Côté, CEO of LMS. “As we
concentrate on increasing our presence in the market, we are pleased to welcome Don to
the leadership team as he brings extensive experience in the patient safety arena from
previous healthcare technology sales and marketing successes."

"LMS offerings represent the next generation of technology dedicated to improving
obstetrical care," said Don. "I am most excited to lead the sales and marketing team that
focuses on making labor and delivery a safer experience for families and for clinicians
alike."

About LMS: LMS is a leader in the application of advanced mathematical modeling
and neural networks for medical use. The LMS CALM Suite provides physicians, nursing
staff, risk managers and hospital administrators with clinical information systems and risk
management tools designed to improve outcomes and patient care for mothers and their
infants during childbirth.

Except for historical information contained herein, the matters discussed in this news release are forward -looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed implied by the forward -looking statements including, but without limitation, economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the CALM product suite, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our distributors, physician training, enforceability and the costs of enforcement of our patents, potential infringements of our patents and the other factors set forth from time to time in the Company’s filings with the United States Securities and Exchange Commission and with the Canadian Securities Commissions. The Company has no intention of or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.